ATOSSA THERAPEUTICS, INC. - 10-Q Summary (Q1 2025)
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2025. Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing proprietary medicines for breast cancer and other breast conditions. The company's lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator (SERM). The company is currently in the research and development phase with no commercial revenue.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(6.7) million | $(5.9) million |
| Operating Expenses | $7.4 million | $7.0 million |
| Research & Development (R&D) | $4.2 million | $3.7 million |
| General & Administrative (G&A) | $3.3 million | $3.2 million |
| Interest Income | $0.7 million | $1.1 million |
| Cash and Cash Equivalents (Ending) | $65.1 million | $84.1 million |
| Net Cash Used in Operating Activities | $(6.0) million | $(4.7) million |
| Working Capital | $63.3 million | N/A |
| Accumulated Deficit | $(218.5) million | $(192.2) million |
Material Changes vs. Prior Period
- Net Loss Increase: Net loss increased by approximately $0.8 million year-over-year, driven primarily by higher operating expenses.
- R&D Expenses: Increased by $0.4 million (11%). This was due to a $0.3 million increase in compensation (headcount growth) and a $0.3 million increase in professional fees (regulatory consulting), partially offset by a $0.1 million decrease in clinical trial spend.
- G&A Expenses: Increased slightly by $0.025 million (1%), primarily due to higher compensation costs.
- Interest Income: Decreased by $0.4 million due to a lower average balance in money market accounts.
- Cash Position: Cash and cash equivalents decreased by approximately $6.0 million during the quarter due to operating cash burn.
Guidance, Outlook, Risks, and Contingencies
- Liquidity Outlook: Management believes current cash resources ($65.1 million) are sufficient to fund operations for at least the next 12 months. The company expects to incur ongoing losses and will need to raise substantial additional capital in the future.
- Strategic Shift: In early 2025, the company decided to pursue a metastatic breast cancer indication for (Z)-endoxifen, aiming for a streamlined regulatory pathway. The company has initiated engagement with the FDA.
- Clinical Updates:
- Karisma Study: Concluded in September 2024; data showed significant reduction in mammographic breast density at 1mg and 2mg doses.
- EVANGELINE Study: Protocol amended in January 2025 to compare (Z)-endoxifen 40mg/day plus ovarian function suppression (OFS) to exemestane plus OFS. The Treatment Cohort initiated in April 2025.
- I-SPY 2 EOP: Enrollment ongoing for a study arm evaluating (Z)-endoxifen in combination with abemaciclib.
- Nasdaq Compliance: On February 21, 2025, the company received notice of non-compliance with Nasdaq Listing Rule 5550(a)(2) due to the stock price failing to maintain a $1.00 minimum closing bid price for 30 consecutive days. The company has until August 20, 2025, to regain compliance.
- Intellectual Property Litigation: On April 3, 2025, Intas Pharmaceuticals Ltd. filed a Post Grant Review (PGR) and an Inter Partes Review (IPR) with the USPTO seeking to invalidate two of the company's patents regarding (Z)-endoxifen. The company intends to vigorously contest these petitions.
- Australian Tax Contingency: The company recorded a $1.5 million liability related to uncertainty regarding the sustainability of its Australian R&D tax rebate position under audit.
Investor Verification Checklist
- Verify the company's ability to regain Nasdaq compliance by August 20, 2025, to avoid potential delisting.
- Monitor the outcome of the Intas Pharmaceuticals patent challenges (PGR and IPR) filed in April 2025, as invalidation could threaten the core IP portfolio.
- Assess the timeline and capital requirements for the amended EVANGELINE trial and the metastatic breast cancer indication strategy.
- Review the status of the Australian R&D tax rebate audit and potential additional liabilities beyond the recorded $1.5 million.
- Track cash burn rates against the $65.1 million cash balance to determine the timing of future capital raises.